Detalhe da pesquisa
1.
S100A9 protein is a novel ligand for the CD85j receptor and its interaction is implicated in the control of HIV-1 replication by NK cells.
Retrovirology
; 10: 122, 2013 Oct 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-24156302
2.
Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial.
Amyotroph Lateral Scler Frontotemporal Degener
; 21(1-2): 5-14, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31280619
3.
Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design.
Trials
; 15: 68, 2014 Feb 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-24571662
4.
Natural killer cell responses to dendritic cells infected by the ANRS HIV-1 vaccine candidate, MVAHIV.
Vaccine
; 32(43): 5577-84, 2014 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25131736
5.
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Lancet Infect Dis
; 14(6): 459-67, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24726095
6.
The CD85j+ NK cell subset potently controls HIV-1 replication in autologous dendritic cells.
PLoS One
; 3(4): e1975, 2008 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-18398485